Want to see DSGN full AI Analyst Report?
Design Therapeutics (DSGN) Drug Pipeline
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Dt-168 | Fuchs Endothelial Corneal Dystrophy, Fuchs | Phase II | Recruiting | DT-168 in Keratoplasty Patients With Fuchs Endothelial Corneal Dystrophy | May 20, 2025 | ― |
| Dt-216P2 | Friedreich Ataxia | phase1AndPhase2 | Recruiting | A Multiple Ascending Dose Study of DT-216P2 in Patients With Friedreich's Ataxia | Feb 25, 2025 | ― |
| Saline, Dt-216P2 | Friedreich Ataxia | Phase I | Not Yet Recruiting | A Single Ascending Dose Study of DT-216P2 in Normal Healthy Participants | Jan 06, 2025 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Dt-168 | Phase II | Fuchs Endothelial Corneal Dystrophy, Fuchs | Recruiting | DT-168 in Keratoplasty Patients With Fuchs Endothelial Corneal Dystrophy | May 20, 2025 | ― |
| Dt-216P2 | phase1AndPhase2 | Friedreich Ataxia | Recruiting | A Multiple Ascending Dose Study of DT-216P2 in Patients With Friedreich's Ataxia | Feb 25, 2025 | ― |
| Saline, Dt-216P2 | Phase I | Friedreich Ataxia | Not Yet Recruiting | A Single Ascending Dose Study of DT-216P2 in Normal Healthy Participants | Jan 06, 2025 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Design Therapeutics, Inc. (DSGN) have in its pipeline
Design Therapeutics DSGN is currently developing the following drugs: Dt-168, Dt-216P2, Saline, Dt-216P2. These drug candidates are in various stages of clinical development as the company works toward FDA approval.
